Literature DB >> 16234484

Identification of a potent inverse agonist at a constitutively active mutant of human P2Y12 receptor.

Zhongren Ding1, Soochong Kim, Satya P Kunapuli.   

Abstract

Human platelets express two P2Y receptors: G(q)-coupled P2Y(1), and G(i)-coupled P2Y(12). Both P2Y(1) and P2Y(12) are ADP receptors on human platelets and are essential for ADP-induced platelet aggregation that plays pivotal roles in thrombosis and hemostasis. Numerous constitutively active G protein-coupled receptors have been described in natural or recombinant systems, but in the P2Y receptors, to date, no constitutive activity has been reported. In our effort to identify G protein coupling domains of the human platelet ADP receptor, we constructed a chimeric hemagglutinin-tagged human P2Y(12) receptor with its C terminus replaced by the corresponding part of human P2Y(1) receptor and stably expressed it in Chinese hamster ovary-K1 cells. It is interesting that the chimeric P2Y(12) mutant exhibited a high level of constitutive activity, as evidenced by decreased cAMP levels in the absence of agonists. The constitutive activation of the chimeric P2Y(12) mutant was dramatically inhibited by pertussis toxin, a G(i) inhibitor. The constitutively active P2Y(12) mutant retained normal responses to 2-methylthio-ADP, with an EC(50) of 0.15 +/- 0.04 nM. The constitutively active P2Y(12) mutant caused Akt phosphorylation that was abolished by the addition of pertussis toxin. Pharmacological evaluation of several P2Y(12) antagonists revealed (E)-N-[1-[7-(hexylamino)-5-(propylthio)-3H-1,2,3-triazolo-[4,5-d]-pyrimidin-3-yl]-1,5,6-trideoxy-beta-d-ribo-hept-5-enofuranuronoyl]-l-aspartic acid (AR-C78511) as a potent P2Y(12) inverse agonist and 5'-adenylic acid, N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-, monoanhydride with (dichloromethylene)bis[phosphonic acid] (AR-C69931MX) as a neutral antagonist. In conclusion, this is the first report of a cell line stably expressing a constitutively active mutant of human platelet P2Y(12) receptor and the identification of potent inverse agonist.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16234484     DOI: 10.1124/mol.105.014654

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

1.  Mutational analysis of residues important for ligand interaction with the human P2Y(12) receptor.

Authors:  Yingying Mao; Lili Zhang; Jianguo Jin; Barrie Ashby; Satya P Kunapuli
Journal:  Eur J Pharmacol       Date:  2010-06-30       Impact factor: 4.432

2.  Pharmacochemistry of the platelet purinergic receptors.

Authors:  Kenneth A Jacobson; Francesca Deflorian; Shilpi Mishra; Stefano Costanzi
Journal:  Purinergic Signal       Date:  2011-02-18       Impact factor: 3.765

3.  P2Y12 receptor antagonism inhibits proliferation, migration and leads to autophagy of glioblastoma cells.

Authors:  Pedro Vargas; Thamiris Becker Scheffel; Fernando Mendonça Diz; Liliana Rockenbach; Nathália Grave; Angélica Regina Cappellari; Luiza Wilges Kist; Maurício Reis Bogo; Marcos Paulo Thomé; Gabriel Fernandes Leal; Amanda de Fraga Dias; Fabrício Figueiró; Eduardo Cremonese Filippi-Chiela; Guido Lenz; Fernanda Bueno Morrone
Journal:  Purinergic Signal       Date:  2022-08-08       Impact factor: 3.950

4.  Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12.

Authors:  Philipp Schmidt; Lars Ritscher; Elizabeth N Dong; Thomas Hermsdorf; Maxi Cöster; Doreen Wittkopf; Jens Meiler; Torsten Schöneberg
Journal:  Mol Pharmacol       Date:  2012-10-23       Impact factor: 4.436

5.  The third intracellular loop stabilizes the inactive state of the neuropeptide Y1 receptor.

Authors:  Melissa J S Chee; Karin Mörl; Diana Lindner; Nicole Merten; Gerald W Zamponi; Peter E Light; Annette G Beck-Sickinger; William F Colmers
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

6.  Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12.

Authors:  Y Zhang; J Ye; L Hu; S Zhang; S H Zhang; Y Li; S P Kunapuli; Z Ding
Journal:  J Thromb Haemost       Date:  2012-10       Impact factor: 5.824

7.  Structural and functional evolution of the P2Y(12)-like receptor group.

Authors:  Torsten Schöneberg; Thomas Hermsdorf; Eva Engemaier; Kathrin Engel; Ines Liebscher; Doreen Thor; Klaas Zierau; Holger Römpler; Angela Schulz
Journal:  Purinergic Signal       Date:  2007-09-06       Impact factor: 3.765

8.  Agonist-bound structure of the human P2Y12 receptor.

Authors:  Jin Zhang; Kaihua Zhang; Zhan-Guo Gao; Silvia Paoletta; Dandan Zhang; Gye Won Han; Tingting Li; Limin Ma; Wenru Zhang; Christa E Müller; Huaiyu Yang; Hualiang Jiang; Vadim Cherezov; Vsevolod Katritch; Kenneth A Jacobson; Raymond C Stevens; Beili Wu; Qiang Zhao
Journal:  Nature       Date:  2014-05-01       Impact factor: 49.962

9.  Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.

Authors:  Riyaad Aungraheeta; Alexandra Conibear; Mark Butler; Eamonn Kelly; Sven Nylander; Andrew Mumford; Stuart J Mundell
Journal:  Blood       Date:  2016-09-30       Impact factor: 22.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.